Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD.

Locations

3 Brazil sites

3 Spain sites

2 France sites

1 United States site

1 Italy site

Age

12 Years to 55 Years Years

Phase

Phase 1

LEARN MORE
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Locations

3 Spain sites

2 Italy sites

1 United States site

Age

12 Years to 55 Years Years

Phase

Phase 2

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).

Locations

9 United States sites

3 Turkey sites

2 Lebanon sites

1 Italy site

1 Kenya site

1 Oman site

Age

12 Years to Years

Phase

Phase 3

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).

Locations

14 United States sites

5 Kenya sites

4 Turkey sites

3 France sites

3 Italy sites

2 Brazil sites

2 Lebanon sites

1 Germany site

1 Saudi Arabia site

1 Oman site

1 Tanzania site

1 United Kingdom site

Age

12 Years to Years

Genotypes

3

Phase

Phase 3

LEARN MORE
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease

This study will evaluate two genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) products - OTQ923 and HIX763 - each reducing the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.

Locations

4 United States sites

1 Italy site

Age

2 Years to 40 Years Years

Genotypes

2

Phase

Phase 1/Phase 2

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

3 United States sites

3 Brazil sites

3 Turkey sites

2 Belgium sites

2 Italy sites

2 Lebanon sites

1 Colombia site

1 France site

1 Oman site

1 Germany site

1 Spain site

Age

6 Months to Years

Phase

Phase 4

LEARN MORE
ESCORT-HU Extension: European Sickle Cell Disease Cohort – Hydroxyurea – Extension

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.

Locations

61 France site

5 Germany sites

4 French Guiana sites

4 Italy sites

2 Guadeloupe sites

2 Martinique sites

1 Greece site

Age

2 Years to Years

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

42 United States sites

4 France sites

4 Spain sites

2 Canada sites

2 Germany sites

2 Italy sites

1 United Kingdom site

Age

12 Years to 65 Years Years

Phase

Phase 2/Phase 3

LEARN MORE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.

Locations

17 United States sites

5 Nigeria sites

4 Egypt sites

4 United Kingdom sites

3 Italy sites

3 Kenya sites

2 Ghana sites

2 Oman sites

2 Saudi Arabia sites

1 France site

Age

2 Years to 14 Years Years

Phase

Phase 3

LEARN MORE